| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.
|
J Clin Oncol
|
2007
|
4.73
|
|
2
|
Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.
|
Int J Radiat Oncol Biol Phys
|
2006
|
4.26
|
|
3
|
Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
|
Int J Radiat Oncol Biol Phys
|
2004
|
3.59
|
|
4
|
Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.
|
Clin Chem
|
2012
|
3.35
|
|
5
|
New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.
|
J Clin Oncol
|
2008
|
2.65
|
|
6
|
Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments.
|
Expert Rev Mol Med
|
2007
|
2.14
|
|
7
|
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.
|
Proc Natl Acad Sci U S A
|
2013
|
2.05
|
|
8
|
Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
|
J Clin Oncol
|
2006
|
1.92
|
|
9
|
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
|
Clin Cancer Res
|
2002
|
1.74
|
|
10
|
WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer.
|
Clin Cancer Res
|
2008
|
1.67
|
|
11
|
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
|
J Clin Oncol
|
2004
|
1.65
|
|
12
|
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
|
J Gen Virol
|
2006
|
1.61
|
|
13
|
Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
|
Radiother Oncol
|
2012
|
1.59
|
|
14
|
Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy.
|
Radiology
|
2010
|
1.52
|
|
15
|
Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group.
|
Cancer
|
2004
|
1.50
|
|
16
|
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
|
PLoS One
|
2008
|
1.47
|
|
17
|
Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers.
|
Proc Natl Acad Sci U S A
|
2007
|
1.43
|
|
18
|
Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
|
Cancer
|
2003
|
1.40
|
|
19
|
Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients.
|
Cancer Res
|
2003
|
1.39
|
|
20
|
Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma.
|
Cancer
|
2005
|
1.38
|
|
21
|
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.36
|
|
22
|
Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes.
|
Clin Chem
|
2003
|
1.35
|
|
23
|
Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy.
|
Ann Surg Oncol
|
2008
|
1.33
|
|
24
|
Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.
|
Cancer Sci
|
2008
|
1.33
|
|
25
|
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.
|
Cancer
|
2014
|
1.33
|
|
26
|
Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.
|
J Proteome Res
|
2006
|
1.29
|
|
27
|
CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis.
|
Cancer Res
|
2009
|
1.27
|
|
28
|
KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas.
|
Cancer Res
|
2010
|
1.26
|
|
29
|
Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
|
Hepatology
|
2008
|
1.25
|
|
30
|
Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
|
Head Neck
|
2003
|
1.25
|
|
31
|
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group.
|
Head Neck
|
2005
|
1.23
|
|
32
|
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.
|
J Gastroenterol Hepatol
|
2011
|
1.22
|
|
33
|
The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas.
|
Lab Invest
|
2007
|
1.19
|
|
34
|
Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells.
|
Carcinogenesis
|
2009
|
1.18
|
|
35
|
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
|
J Clin Oncol
|
2012
|
1.17
|
|
36
|
Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.
|
Clin Cancer Res
|
2003
|
1.16
|
|
37
|
The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry.
|
Arch Pathol Lab Med
|
2007
|
1.16
|
|
38
|
Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
|
Med Dosim
|
2007
|
1.14
|
|
39
|
The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma.
|
Clin Cancer Res
|
2010
|
1.13
|
|
40
|
WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma.
|
Cancer Biol Ther
|
2010
|
1.12
|
|
41
|
Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
|
Br J Haematol
|
2007
|
1.07
|
|
42
|
Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
|
Cancer
|
2013
|
1.07
|
|
43
|
The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors.
|
PLoS One
|
2011
|
1.05
|
|
44
|
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
|
Invest New Drugs
|
2007
|
1.04
|
|
45
|
A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma.
|
Radiother Oncol
|
2011
|
1.04
|
|
46
|
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG).
|
Radiother Oncol
|
2006
|
1.04
|
|
47
|
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
|
Cancer Lett
|
2007
|
1.03
|
|
48
|
Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine.
|
Am J Clin Oncol
|
2005
|
1.03
|
|
49
|
Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods.
|
Radiother Oncol
|
2004
|
1.03
|
|
50
|
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
|
Cancer Chemother Pharmacol
|
2007
|
1.00
|
|
51
|
EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines.
|
J Immunol
|
2008
|
0.99
|
|
52
|
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.
|
Cancer Res
|
2013
|
0.97
|
|
53
|
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
|
Invest New Drugs
|
2009
|
0.97
|
|
54
|
Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients.
|
Clin Cancer Res
|
2008
|
0.97
|
|
55
|
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.
|
Invest New Drugs
|
2009
|
0.96
|
|
56
|
Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.
|
Expert Rev Anticancer Ther
|
2006
|
0.96
|
|
57
|
Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
|
Clin Chem
|
2003
|
0.96
|
|
58
|
Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas.
|
Epigenetics
|
2007
|
0.95
|
|
59
|
Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
|
Clin Cancer Res
|
2003
|
0.95
|
|
60
|
FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma.
|
Carcinogenesis
|
2013
|
0.95
|
|
61
|
A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas.
|
Mol Cancer Res
|
2012
|
0.94
|
|
62
|
Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma.
|
J Proteome Res
|
2006
|
0.94
|
|
63
|
Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
|
Support Care Cancer
|
2010
|
0.93
|
|
64
|
CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
|
Cancer Immunol Immunother
|
2008
|
0.93
|
|
65
|
An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results.
|
J Clin Oncol
|
2005
|
0.92
|
|
66
|
An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
|
Biochem Pharmacol
|
2010
|
0.92
|
|
67
|
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.
|
Invest New Drugs
|
2012
|
0.92
|
|
68
|
Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.91
|
|
69
|
Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011.
|
J Gastroenterol Hepatol
|
2012
|
0.90
|
|
70
|
Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?
|
Future Oncol
|
2009
|
0.90
|
|
71
|
Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
|
Invest New Drugs
|
2013
|
0.90
|
|
72
|
Reduced plasma RNA integrity in nasopharyngeal carcinoma patients.
|
Clin Cancer Res
|
2006
|
0.90
|
|
73
|
Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma.
|
Arch Pathol Lab Med
|
2008
|
0.89
|
|
74
|
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.
|
Invest New Drugs
|
2009
|
0.88
|
|
75
|
Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas.
|
Cell Mol Life Sci
|
2013
|
0.88
|
|
76
|
Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer.
|
Clin Cancer Res
|
2008
|
0.88
|
|
77
|
Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma.
|
World J Gastroenterol
|
2005
|
0.87
|
|
78
|
International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study.
|
Chin J Cancer
|
2014
|
0.87
|
|
79
|
The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation.
|
Mol Cancer Res
|
2013
|
0.86
|
|
80
|
Comparison of protocols for extracting circulating DNA and RNA from maternal plasma.
|
Clin Chem
|
2005
|
0.85
|
|
81
|
Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.
|
Clin Chem
|
2005
|
0.85
|
|
82
|
Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
|
Cancer
|
2004
|
0.85
|
|
83
|
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.
|
Clin Cancer Res
|
2013
|
0.85
|
|
84
|
Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
|
Clin Cancer Res
|
2008
|
0.85
|
|
85
|
Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein.
|
Clin Chem
|
2002
|
0.85
|
|
86
|
The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma.
|
Oral Oncol
|
2008
|
0.84
|
|
87
|
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma.
|
Cancer
|
2011
|
0.84
|
|
88
|
Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1.
|
Biochem Pharmacol
|
2009
|
0.84
|
|
89
|
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
|
Cancer
|
2002
|
0.84
|
|
90
|
Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
|
J Med Virol
|
2002
|
0.83
|
|
91
|
Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes.
|
Epigenomics
|
2014
|
0.83
|
|
92
|
Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
|
Invest New Drugs
|
2010
|
0.83
|
|
93
|
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
|
Asia Pac J Clin Oncol
|
2015
|
0.82
|
|
94
|
Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.
|
J Oncol
|
2009
|
0.82
|
|
95
|
Treatment strategy and clinical experience.
|
Semin Cancer Biol
|
2002
|
0.81
|
|
96
|
Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma.
|
Clin Chem
|
2004
|
0.81
|
|
97
|
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
|
Anticancer Drugs
|
2002
|
0.81
|
|
98
|
Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma.
|
Liver Int
|
2011
|
0.81
|
|
99
|
Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.81
|
|
100
|
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
101
|
Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor.
|
Oral Oncol
|
2006
|
0.80
|
|
102
|
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas.
|
Clin Cancer Res
|
2004
|
0.80
|
|
103
|
Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study.
|
Oncology
|
2007
|
0.79
|
|
104
|
Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16.
|
J Cell Biochem
|
2008
|
0.79
|
|
105
|
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
|
Invest New Drugs
|
2012
|
0.78
|
|
106
|
Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study.
|
J Vasc Interv Radiol
|
2008
|
0.78
|
|
107
|
Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions.
|
Clin Chem
|
2003
|
0.78
|
|
108
|
Automated extraction protocol for quantification of SARS-coronavirus RNA in serum: an evaluation study.
|
BMC Infect Dis
|
2006
|
0.78
|
|
109
|
Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
|
Hong Kong Med J
|
2010
|
0.77
|
|
110
|
A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.
|
Acta Oncol
|
2004
|
0.77
|
|
111
|
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
|
Oncology
|
2005
|
0.77
|
|
112
|
A novel application of plasma and cerebrospinal fluid level of epstein barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report.
|
Oncology
|
2008
|
0.76
|
|
113
|
The effect of centrifugation on circulating mRNA quantitation opens up a new scenario in expression profiling from patients with metastatic colorectal cancer.
|
Clin Biochem
|
2007
|
0.76
|
|
114
|
False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels.
|
AJR Am J Roentgenol
|
2004
|
0.76
|
|
115
|
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
|
Cancer
|
2013
|
0.76
|
|
116
|
Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma.
|
BMC Cancer
|
2006
|
0.76
|
|
117
|
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.76
|
|
118
|
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma.
|
Acta Oncol
|
2005
|
0.75
|
|
119
|
A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma.
|
Radiother Oncol
|
2003
|
0.75
|
|
120
|
Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma.
|
Head Neck
|
2010
|
0.75
|